BiotechTube

MK0633

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis

Trial Timeline

Nov 1, 2006 → Jan 1, 2007

NCT ID
NCT00421278

About MK0633

MK0633 is a phase 2 stage product being developed by Merck for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00421278. Target conditions include Atherosclerosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00768170Phase 1Completed
NCT00421278Phase 2Completed

Competing Products

20 competing products in Atherosclerosis

See all competitors
ProductCompanyStageHype Score
Orforglipron + PlaceboEli LillyPhase 3
77
Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3
77
Pactimibe sulfateDaiichi SankyoPhase 2/3
65
PactimibeDaiichi SankyoPhase 2
52
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3
77
Micronized 17B-estradiolJohnson & JohnsonPhase 2/3
65
Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
85
Rosuvastatin + PlaceboAstraZenecaApproved
85
rosuvastatin + placeboAstraZenecaPhase 1
33
Rosuvastatin + PlaceboAstraZenecaPhase 1
33
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
Vorapaxar + Placebo + Aspirin + ClopidogrelMerckPhase 2
52
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
85
lovastatinMerckPhase 2/3
65
Ezetimibe + PlaceboMerckApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
NiaspanMerckPre-clinical
23

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85